公开(公告)号：EP4389130A1

公开(公告)日：2024-06-26

申请号：EP22857846.4

申请日：2022-08-17

申请人： Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. ,  Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.

发明人： WANG, Yandong ,  SU, Yingxue ,  CAO, Chen ,  WU, Meirong ,  XUE, Yaping ,  YU, Chuiliang

IPC分类号： A61K31/575 ,  A61P27/12

CPC分类号： A61K31/575 ,  A61P27/12

摘要： An application of a steroid compound in the preparation of a drug for preventing and/or treating eye floaters. The steroid compound can have good therapeutic, alleviative, and preventive effects on eye floaters, can alleviate and/or cure eye floaters to a great extent, and can improve visual clarity.

公开(公告)号：EP4397670A1

公开(公告)日：2024-07-10

申请号：EP22863467.1

申请日：2022-08-30

申请人： Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. ,  Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.

发明人： YU, Chuiliang ,  LI, Xiaolin ,  WANG, Yandong ,  LAN, Xiaobing ,  HAO, Fei ,  SU, Yingxue ,  HE, Haiying ,  WU, Meirong

IPC分类号： C07J9/00

CPC分类号： C07J9/00

摘要： A steroidal compound, a preparation method therefor and an application thereof. On one hand, provided are a compound represented by formula I, a preparation method therefor, and an application thereof in a method for separating and purifying lanosterol; on the other hand, provided is the method for separating and purifying lanosterol. The method is simple to operate, stable in process, high in productivity and low in cost, and the obtained lanosterol has high purity and can meet medical application thereof.

公开(公告)号：EP3828193A1

公开(公告)日：2021-06-02

申请号：EP19841413.8

申请日：2019-07-25

申请人： Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd.

发明人： LIU, Yizhi ,  WANG, Yandong ,  LI, Xiaolin ,  LUO, Zhi ,  HE, Haiying ,  LI, Jian ,  CHEN, Shuhui

IPC分类号： C07J9/00 ,  A61K9/08 ,  A61K31/573 ,  A61P27/12

摘要： The present invention relates to a crystal form of a compound of formula (I) and an application thereof in preparing a drug for treating an ophthalmic disease.

公开(公告)号：EP4389131A1

公开(公告)日：2024-06-26

申请号：EP22857847.2

申请日：2022-08-17

申请人： Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. ,  Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.

发明人： WANG, Yandong ,  SU, Yingxue ,  CAO, Chen ,  ZHOU, Sheng'an ,  XUE, Yaping ,  WU, Meirong ,  YU, Chuiliang

IPC分类号： A61K31/575 ,  A61K47/38 ,  A61K47/40 ,  A61K47/26 ,  A61K47/34 ,  A61K47/10 ,  A61K9/08 ,  A61K9/107 ,  A61K9/70 ,  A61P27/12 ,  A61P27/02

CPC分类号： A61K9/70 ,  A61K47/40 ,  A61K31/575 ,  A61K9/107 ,  A61P27/12 ,  A61K47/10 ,  A61K47/34 ,  A61K47/26 ,  A61K47/38 ,  A61P27/02 ,  A61K9/08

摘要： A pharmaceutical composition, a preparation method therefor and an application thereof. The pharmaceutical composition comprises the following components : a compound represented by formula I, hydroxypropyl methyl cellulose, benzalkonium chloride, and a pH regulator. The pharmaceutical composition can be used for preparing drugs for preventing or treating cataracts. The pharmaceutical composition has excellent stability in respect of exposure to light and to high temperatures, can be stored at room temperature, is convenient for patients to use, has pH and osmotic pressure close to those in the intraocular environment, is uniform in particle size distribution, and thus can give the patients good comfort.

公开(公告)号：EP3988544A1

公开(公告)日：2022-04-27

申请号：EP20827811.9

申请日：2020-06-22

申请人： Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd.

发明人： LIU, Yizhi ,  WANG, Yandong ,  WU, Lingyun ,  YOU, Xu ,  XIAO, Zheming ,  CHEN, Shuhui

IPC分类号： C07D401/12 ,  C07D401/14 ,  A61K31/551 ,  A61P7/02 ,  A61P9/10 ,  A61P9/08 ,  A61P27/06 ,  A61P9/12

摘要： Disclosed are a series of isoquinolone derivatives as ROCK protein kinase inhibitors and uses thereof in preparing medicaments for ROCK protein kinase inhibitor-related glaucoma or ocular hypertension diseases. Specially, disclosed are a compound of formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

公开(公告)号：EP4368180A1

公开(公告)日：2024-05-15

申请号：EP22837064.9

申请日：2022-07-08

申请人： Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. ,  Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.

发明人： LIANG, Chiyong ,  WANG, Yandong ,  YU, Chuiliang ,  LI, Liang ,  XUE, Yaping ,  WU, Meirong

IPC分类号： A61K31/192 ,  A61P27/02 ,  A61P29/00

CPC分类号： A61P29/00 ,  A61K31/192 ,  A61P27/02

摘要： The present invention relates to an application of loxoprofen sodium or a composition containing loxoprofen sodium in the preparation of a drug for preventing and/or treating the dry eye disease.

公开(公告)号：EP4368179A1

公开(公告)日：2024-05-15

申请号：EP22837063.1

申请日：2022-07-08

申请人： Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. ,  Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.

发明人： ZHOU, Shengan ,  YU, Chuiliang ,  WANG, Yandong ,  FENG, Ximing ,  LI, Yaxiong ,  WU, Meirong

IPC分类号： A61K31/192 ,  A61K9/08 ,  A61K9/06 ,  A61K9/70 ,  A61K47/36 ,  A61K47/26 ,  A61P27/02

CPC分类号： A61K9/70 ,  A61K47/26 ,  A61K31/192 ,  A61K47/36 ,  A61P27/02 ,  A61K9/06 ,  A61K9/08

摘要： A composition containing loxoprofen sodium. The composition comprises loxoprofen sodium, sodium hyaluronate and polysorbate 80, wherein the molecular weight of sodium hyaluronate is 0.8 × 106 - 1.6 × 106. The composition has good stability and a long shelf life and is convenient to use.

公开(公告)号：EP4309675A1

公开(公告)日：2024-01-24

申请号：EP21931034.9

申请日：2021-06-08

申请人： Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd.

发明人： WANG, Yandong ,  LIU, Guoqiang ,  LIU, Wei

IPC分类号： A61K47/54 ,  A61K31/635 ,  A61K9/08 ,  A61P27/02 ,  A61P29/00

摘要： Disclosed are a prodrug of celecoxib represented by Formula I, a preparation method therefor and an application thereof. The compound has proper solubility and is relatively stable under storage conditions. Pharmacokinetic experiments show that celecoxib can be detected in ocular tissues and is distributed in cornea, conjunctiva and aqueous humor, and the celecoxib achieves a relatively high drug concentration and thus the compound of Formula I is an excellent celecoxib prodrug. Moreover, the distribution of control compound SZY1907-P4 is almost not detected, and the concentration of eye drops prepared from the celecoxib in the cornea, conjunctiva and aqueous humor is also relatively low. The compound of Formula I has a remarkable absorption advantage, the drug concentration in the ocular tissues is remarkably higher than those of the celecoxib group and control group SZY1907-P4, and thus the compound can be prepared into liquid preparations, such as eye drops and injections, for inflammatory reactions.

公开(公告)号：EP4265606A1

公开(公告)日：2023-10-25

申请号：EP21909417.4

申请日：2021-12-21

申请人： Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. ,  Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.

发明人： GE, Jian ,  WANG, Yandong ,  LIU, Yizhi ,  WU, Lingyun ,  YOU, Xu ,  XIAO, Zheming ,  CHEN, Shuhui

IPC分类号： C07D401/12 ,  A61P27/06 ,  A61P7/02 ,  A61P9/10 ,  A61P9/12 ,  A61K31/551 ,  A61P9/08

摘要： Disclosed is a salt form of an isoquinolinone type compound as a ROCK protein kinase inhibitor and a preparation method therefor, and use of the salt form in the preparation of a medicament for treating glaucoma or ocular hypertension is further included.